Delayed antifungal therapy strongly linked to mortality in Candida septic shock

A retrospective cohort study of 850 adult patients with culture-positive Candida septic shock across 32 hospitals found that delay in initiating pathogen-appropriate antifungal therapy after onset of persistent hypotension was the strongest predictor of hospital survival. Survival was 86% when appropriate antifungal therapy was given within 2 hours of hypotension onset, declining about 5% per hour thereafter; the adjusted odds of death increased 1.045-fold per hour of delay. The study reported that median time to appropriate therapy was 32.3 hours, with only 16.9% of patients treated within 6 hours.

Most relevant for: Critically ill patients with Candida septic shock being managed in the ICU.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.